JOURNAL OF INTERNATIONAL CRISIS AND RISK COMMUNICATION RESEARCH
ISSN: 2576-0017
2024, VOL 7, NO S10

Postpartum Depression: Endocrine Factors, Biochemical Markers, and the Role of Nursing Interventions

Awatef Fahat Alanezi[1], Aisha Hafiz Ibrahim[2], Nesreen Hafiz Ibrahim[2], Eman Hafiz Ibrahim[2], Haya Mohammed Alqousi[3], Mona Faraj Alonazi[3], Meshari Zayed Almutairi[4], Abdulmajeed Mualla Alotaibi[4], Fahad Sulaiman Almousa[4], Salehah Ali Alshomrani[5]

1. Ksa, ministry of health Almuroj
2. Ksa, ministry of health, Al murooj PHC
3. Ksa, ministry of health, Riyadh Second Health Cluster
4. Ksa, ministry of health, King Fahad Medical City
5. Ksa, ministry of health, Western Tuwaiq

ABSTRACT

Background: Postpartum depression (PPD) is a complex mental health illness affecting around 10–20% of women worldwide, with significant repercussions for maternal, neonatal, and familial health. It is characterized by emotional, behavioral, and cognitive disturbances that emerge weeks to months after childbirth. Recent study highlights the significant impact of endocrine changes, including as fluctuations in estrogen, progesterone, and cortisol, on the onset and progression of postpartum depression (PPD). Furthermore, physiological indicators including inflammatory cytokines, serotonin levels, and disruption of the hypothalamic-pituitary-adrenal (HPA) axis are increasingly recognized as contributing factors. Despite advancements in acknowledging these features, a notable shortcoming remains in integrating this information into nursing practice for early detection, thorough treatment, and prevention. Aim: The paper aims to elucidate the endocrine and biochemical mechanisms associated with postpartum depression (PPD), assess its impact on maternal mental health, and identify evidence-based nursing interventions that mitigate the effects of PPD. Methods: A comprehensive assessment of the current literature was conducted, focusing on hormonal fluctuations, biochemical pathways, and their interrelations in postpartum depression (PPD). The influence of nursing interventions on these physiological and psychological attributes was evaluated. Results: Postpartum depression (PPD) has been found to have a substantial correlation with sudden hormonal variations that occur after childbirth. These fluctuations, particularly decreases in estrogen and progesterone levels, are known to disrupt neurotransmitter systems. There are a number of biochemical markers that contribute to the intensification of depressive symptoms. These markers include increased inflammatory cytokines, decreased serotonin activity, and dysregulated cortisol secretion. A significant amount of potential for improvement in outcomes has been demonstrated by nursing interventions that address these characteristics. These

interventions include patient education, screening devices, aid with medication adherence, and lifestyle counseling. Conclusion: Endocrine changes, physiological markers, and psychological factors interact intricately to cause postpartum depression, a complex disorder. By providing early detection, all-encompassing care, and education, nurses play a crucial role in treating PPD. Personalized nursing interventions and biomarker-driven diagnostics are a promising strategy for improving PPD therapy and prevention. In order to improve the health outcomes for mothers and newborns, future research must focus on confirming specific biomarkers and developing customized interventions.

KEYWORDS: Postpartum depression, hormonal changes, biochemical markers, nursing, psychological support, therapeutic interventions.

1. Introduction

Postpartum depression (PPD) is a notable public health issue, impacting roughly one in five women within the first year following childbirth [1, 2]. PPD is diagnosed in women post-partum. This condition is defined by a constellation of depressive symptoms, including persistent sadness, irritability, and cognitive impairments, among others. The mother's ability to provide necessary care for her newborn may be impeded by these symptoms. The illness substantially affects the child's development, heightening the risk of behavioral and emotional disorders and diminishing bonding potential, while also endangering the mother's health [3, 4]. Postpartum depression, commonly referred to as PPD, is a complex condition influenced by various factors, including genetics, psychology, social environment, and biology. Metabolic dysregulations and endocrine system abnormalities significantly influence the emergence of depression symptoms [5, 6]. Throughout gestation, the concentrations of estrogen and progesterone in the body experience a significant elevation, peaking in the third trimester. Conversely, these levels experience a rapid decline within hours of delivery, resulting in a disruption of neurotransmitter control, particularly serotonin and dopamine, essential for mood stability [7, 8]. Moreover, postpartum cortisol, a crucial hormone of the hypothalamic-pituitary-adrenal (HPA) axis, demonstrates considerable dysregulation, facilitating the emergence of depressive symptoms and amplifying stress reactions [9, 10].

A multitude of biochemical indicators has been linked to the etiology of postpartum depression (PPD), which is defined by alterations in hormone levels. The symptoms of PPD exhibit these oscillations. A significant proportion of women with postpartum depression (PPD) exhibit higher levels of inflammatory cytokines. The cytokines encompass tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), which signify the activation of immune-inflammatory pathways [11, 12]. Brain-derived neurotrophic factor (BDNF), a protein essential for neuroplasticity, has been noted to decrease during the postpartum period [13, 14]. These observations have been conducted during the entirety of the postpartum period. Consequently, it seems that both cognitive performance and adaptability are deteriorating over this timeframe. The dysregulation of the HPA axis, seen by abnormal cortisol rhythms, is an additional factor that contributes to the stress sensitivity and mood disorders

observed in postpartum women. The integration of findings from biochemical and endocrine research into nursing practice remains constrained, despite an increasing understanding of these physiological systems. Nurses, as main caregivers, are crucial in diagnosing early signs of postpartum depression (PPD), administering targeted medication, and educating patients about the physiological basis of the disorder. This study aims to examine the endocrine and biochemical underpinnings of postpartum depression (PPD), emphasize the importance of these findings for nursing practice, and promote an evidence-based perspective on maternal mental health treatment.



Figure 1 Activation of T3 and T4 hormones and negative feedback mechanism involved in PPD.

Endocrine Factors in Postpartum Depression

Fluctuations in Hormones

Estrogen and Progesterone

The pathophysiology of postpartum depression (PPD) is closely linked to the substantial endocrine event of the rapid decrease in estrogen and progesterone levels after childbirth. During pregnancy, there is a substantial elevation in hormones, with estrogen levels attaining unparalleled peaks and progesterone levels rising by up to 50 times their baseline amounts. This increase is essential for maintaining pregnancy and preparing the body for childbirth; nevertheless, both hormones undergo a substantial decrease to levels akin to those before pregnancy within hours of delivery [17, 18].

The impact of this hormonal cessation on the central nervous system (CNS) is significant, especially concerning the neurotransmitter pathways associated with

mood regulation. Estrogen modulates the production, release, and receptor sensitivity of essential neurotransmitters, such as serotonin and dopamine, therefore exerting neuroprotective and mood-stabilizing effects. It enhances neuroinflammation and augments synaptic plasticity, both of which are crucial for emotional control [21]. Progesterone and its neuroactive metabolite allopregnanolone have anxiolytic and depressive effects through its interaction with the gamma-aminobutyric acid (GABA) system, the principal inhibitory neurotransmitter pathway in the brain [22, 23]. The sudden withdrawal of these hormones after childbirth can disturb neurotransmitter balance, leading to the emergence of depression symptoms.

This hormonal association has been further corroborated by clinical studies. Experimental studies indicate that women who suffer postpartum depression (PPD) exhibit heightened sensitivity to typical postpartum hormone variations compared to those who do not. The causative involvement of these hormones in the etiology of postpartum depression (PPD) is highlighted by the decrease in depressive symptoms noted in experimental investigations employing hormone stabilization techniques that sustain estrogen and progesterone levels following delivery [25].

Cortisol and the Hypothalamic-Pituitary-Adrenal (HPA) Axis

Cortisol, the final product of the hypothalamic-pituitary-adrenal (HPA) axis, is a critical component of the body's stress respond. The maternal HPA axis is stimulated by the placental secretion of corticotropin-releasing hormone (CRH), which results in a substantial increase in cortisol levels during pregnancy. This hormonal axis endures rapid readjustment following childbirth as the placenta is expelled, resulting in transient HPA axis dysregulation [26, 27].

Depressive and anxiety disorders, such as PPD, have been extensively linked to dysfunctional cortisol secretion patterns. Women with PPD frequently demonstrate exaggerated cortisol reactivity, altered diurnal cortisol rhythms, and attenuated cortisol responses to stress, which are indicative of maladaptive HPA axis function [28, 29]. These modifications have the potential to further exacerbate emotional dysregulation, increase vulnerability to stressors, and impede the bond between mothers and infants. This dysregulation is further exacerbated by the interaction between cortisol and other endocrine systems, such as estrogen-mediated HPA axis feedback [30].

Cortisol is involved in the affective processing of information by interacting with brain regions such as the hippocampus, prefrontal cortex, and amygdala, in addition to its role in stress adaptation. The pathophysiology of PPD is influenced by dysregulated cortisol secretion, which can impair neurogenesis, reduce synaptic connectivity, and heighten amygdala reactivity [31]. Stress management techniques and pharmacological modulation, which are interventions that are designed to normalize HPA axis function, have demonstrated potential in alleviating depressive symptoms in mothers who have been affected [32].



Figure 2Hypothalamic-Pituitary-Adrenal (HPA) Axis

Prolactin and Oxytocin

Prolactin and oxytocin, commonly known as "maternal hormones," are crucial in facilitating maternal actions, fostering bonding, and enhancing emotional well-being throughout the postpartum phase. Prolactin, primarily recognized for its function in lactation, also has considerable effects on the central nervous system. It regulates dopaminergic pathways in the hypothalamus and limbic system, areas that control maternal motivation and reward behaviors [33, 34]. Dysregulated prolactin levels have been associated with mood problems, particularly postpartum depression (PPD). Hyperprolactinemia has been linked to heightened emotional lability and depressive symptoms, although its exact involvement in postpartum depression is still under active investigation [35].

Oxytocin, commonly referred to as the "love hormone," promotes social bonding and enhances stress resilience. Secreted in significant quantities during parturition and lactation, it fosters maternal-infant bonding and alleviates stress by suppressing amygdala hyperactivity and facilitating parasympathetic nervous system predominance [36]. Women with postpartum depression frequently demonstrate diminished oxytocin responses to stimuli associated with infants, which correlates with decreased bonding and increased anxiety [37]. Furthermore, the interaction of oxytocin with other systems, particularly its estrogen-mediated overexpression, highlights the intricacy of its function in postpartum mental health [38].

Therapeutic approaches aimed at these hormones, like exogenous oxytocin injection or prolactin-modulating medications, have demonstrated potential in treating postpartum depression (PPD). Nursing therapies that prioritize skin-to-skin contact and breastfeeding support can facilitate natural oxytocin release, hence enhancing maternal mood and bonding experiences [39, 40].

Biochemical Markers in Postpartum Depression

Neurotransmitter Dysregulation

Serotonin

Serotonin (5-hydroxytryptamine, 5-HT) is a critical neurotransmitter involved in mood regulation, and its dysregulation has been extensively linked to depressive disorders, including postpartum depression (PPD). The serotonergic system's functioning is modulated by hormonal changes during the postpartum period, particularly by the sharp decline in estrogen, which affects serotonin synthesis, receptor binding, and reuptake efficiency [41]. Estrogen facilitates the expression of tryptophan hydroxylase, the rate-limiting enzyme in serotonin synthesis, and regulates serotonin receptor sensitivity, especially 5-HT1A and 5-HT2A subtypes, which are implicated in mood stabilization [42, 43].

Postpartum women with PPD have been observed to exhibit reduced central serotonin levels and altered receptor binding, contributing to depressive symptoms such as sadness, irritability, and lethargy [44]. Imaging studies, including positron emission tomography (PET), reveal reduced serotonin transporter (SERT) availability in the postpartum period, a phenomenon further exacerbated in individuals with PPD [45]. These findings underscore the need for serotonergic-targeted interventions, such as selective serotonin reuptake inhibitors (SSRIs), which have shown efficacy in mitigating depressive symptoms by enhancing serotonergic transmission [46].

Dopamine

Dopamine, another neurotransmitter, plays a vital role in reward processing, motivation, and anhedonia, a core symptom of PPD. The dopaminergic system, primarily regulated by the mesolimbic and mesocortical pathways, is sensitive to hormonal fluctuations postpartum. Estrogen modulates dopamine synthesis and receptor activity, particularly in the nucleus accumbens and prefrontal cortex, regions critical for emotional and motivational processing [47].

In PPD, dopaminergic dysfunction manifests as reduced dopamine synthesis and blunted dopaminergic responses to rewarding stimuli, correlating with anhedonia and impaired maternal-infant bonding [48]. Studies have demonstrated lower dopamine receptor D2/D3 binding potential in postpartum women experiencing depressive symptoms, further implicating dopaminergic dysregulation in PPD pathophysiology [49]. Pharmacological and behavioral interventions targeting dopaminergic pathways, such as dopamine agonists or reward-based therapies, may hold promise in addressing these deficits.

Inflammatory Markers

Elevated levels of pro-inflammatory cytokines are increasingly recognized as critical contributors to PPD, reflecting an activation of immune-inflammatory pathways during the postpartum period. Pregnancy induces a state of immunological adaptation, transitioning from a pro-inflammatory to an anti-inflammatory profile to support fetal tolerance. However, postpartum, this balance is disrupted, often resulting in a rebound pro-inflammatory state [50].

Cytokines such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and C-reactive protein (CRP) have been found to be elevated in women with PPD, correlating with the severity of depressive symptoms [51, 52]. These inflammatory markers can cross the blood-brain barrier and influence central nervous system (CNS) function by altering neurotransmitter metabolism, reducing synaptic plasticity, and activating microglia, leading to neuroinflammation [53]. IL-6, in particular, disrupts serotonin signaling and neurogenesis, while TNF-α modulates glutamatergic and GABAergic neurotransmission, both of which are critical for emotional regulation [54].

The association between inflammatory markers and PPD suggests potential therapeutic avenues, including anti-inflammatory agents and lifestyle interventions such as exercise and dietary modifications, which have been shown to modulate inflammatory responses and improve mood [55].

Brain-Derived Neurotrophic Factor (BDNF)

BDNF is a neurotrophin critical for neurogenesis, synaptic plasticity, and neuronal survival, processes essential for emotional and cognitive health. Reduced BDNF levels have been consistently linked to mood disorders, including PPD. Pregnancy and the postpartum period are characterized by fluctuations in BDNF levels, which are influenced by hormonal changes, particularly estrogen and cortisol [56].

Women with PPD exhibit significantly lower serum and cerebrospinal fluid (CSF) BDNF levels compared to non-depressed postpartum women, suggesting impaired neuroplasticity and neuronal resilience [57, 58]. Low BDNF levels in the hippocampus and prefrontal cortex, brain regions implicated in mood regulation, further exacerbate depressive symptoms by impairing neurogenesis and synaptic connectivity [59]. Animal studies support these findings, demonstrating that exogenous BDNF administration can reverse depressive-like behaviors induced by postpartum hormonal withdrawal [60].

Interventions aimed at enhancing BDNF levels, such as antidepressants, exercise, and dietary supplementation with omega-3 fatty acids, have shown efficacy in improving mood and cognitive function in women with PPD [61].

HPA Axis Dysregulation

The hypothalamic-pituitary-adrenal (HPA) axis is a central stress-regulatory system that undergoes significant adaptation during pregnancy and postpartum. Cortisol, the primary effector hormone of the HPA axis, plays a dual role during the perinatal period: it supports fetal development and prepares the mother for the physiological and psychological demands of childbirth. However, postpartum, the HPA axis must recalibrate, a process that is often dysregulated in women with PPD [62].

Women with PPD commonly exhibit abnormal diurnal cortisol rhythms, including flattened morning peaks and elevated evening levels, which are associated with increased stress sensitivity and emotional dysregulation [63]. Additionally, heightened cortisol reactivity to stress, reflecting hyperactivity of the HPA axis, has been observed in affected individuals, further exacerbating depressive symptoms [64]. This dysregulation can disrupt feedback inhibition mechanisms mediated by

glucocorticoid receptors, perpetuating a cycle of heightened stress reactivity [65].

The interaction between cortisol and other biochemical markers, such as inflammatory cytokines and neurotransmitters, amplifies the impact of HPA axis dysfunction on mood regulation. Targeted interventions, including stress management techniques, mindfulness-based therapies, and pharmacological agents such as glucocorticoid receptor antagonists, have shown potential in restoring HPA axis balance and alleviating PPD symptoms [66].



Figure 3 Adrenal Fatigue or HPA Axis Dysfunction

Role of Nursing in Postpartum Depression Management

Patient Education and Early Identification

Nursing professionals play a pivotal role in the early identification of postpartum depression (PPD) by educating mothers about the hormonal and psychological changes that occur during the postpartum period. Educating mothers about the symptoms of PPD, including persistent sadness, fatigue, irritability, and difficulties bonding with the infant, is essential for fostering awareness and reducing stigma. Research has shown that increased maternal awareness of PPD symptoms improves early reporting and treatment-seeking behaviors, thereby mitigating long-term adverse outcomes for both mother and child [67, 68].

Utilizing standardized screening tools like the Edinburgh Postnatal Depression Scale (EPDS) is another crucial component of early identification. The EPDS is a validated questionnaire specifically designed for screening PPD, and it has been widely used in clinical and community settings to identify women at risk [69]. Nurses are instrumental in administering the EPDS during routine postnatal check-ups, interpreting the results, and referring at-risk mothers for further assessment and intervention. Early identification through these means allows for timely therapeutic measures, reducing the severity and duration of PPD symptoms [70].

Psychoeducation and Counseling

Nurses are uniquely positioned to provide psychoeducation and counseling to

postpartum women, addressing the stigma associated with mental health conditions and fostering open communication. Stigma remains a significant barrier to seeking care, as many mothers fear judgment or feel shame about experiencing PPD [71]. By normalizing the experience of emotional challenges during the postpartum period and emphasizing the biological and psychosocial underpinnings of PPD, nurses can create a supportive environment that encourages mothers to seek help.

Counseling sessions led by nurses often include teaching stress management techniques, such as mindfulness, relaxation exercises, and time management strategies. These techniques help mothers build resilience and reduce the emotional and physical strain associated with caring for a newborn [72]. Moreover, psychoeducation about the importance of self-care and prioritizing mental health equips mothers with practical tools to cope with the demands of motherhood.

Monitoring and Medication Management

Nurses play a critical role in coordinating with healthcare providers to ensure appropriate pharmacological interventions for PPD, including hormonal therapies or antidepressants, are implemented when necessary. Hormonal treatments, such as estrogen supplementation, have been explored as potential therapies for PPD, particularly for mothers whose depressive symptoms are linked to abrupt postpartum hormonal changes [73]. Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), remain a cornerstone of treatment for moderate to severe PPD [74].

In addition to facilitating access to these treatments, nurses are responsible for educating mothers about the potential side effects of prescribed medications, the importance of adherence to treatment regimens, and strategies for managing adverse effects [75]. For breastfeeding mothers, nurses also provide guidance on the safety profiles of antidepressants and hormonal therapies, ensuring that both maternal and infant health are prioritized. Close monitoring of treatment efficacy and side effects is essential, as it allows for timely adjustments to the therapeutic plan and ensures optimal outcomes [76].

Supportive Care and Lifestyle Counseling

Supportive care is a cornerstone of nursing interventions for PPD, with an emphasis on promoting balanced nutrition, sleep hygiene, and physical activity. Proper nutrition, including a diet rich in omega-3 fatty acids, vitamins, and minerals, has been associated with improved mood and reduced depressive symptoms in postpartum women [77]. Similarly, promoting good sleep hygiene is vital, as sleep deprivation is a significant risk factor for PPD. Nurses can provide practical advice on managing infant sleep patterns and utilizing support systems to ensure mothers receive adequate rest [78].

Physical activity, even in moderate forms such as walking or yoga, has demonstrated efficacy in alleviating depressive symptoms by enhancing endorphin release and improving overall well-being [79]. Nurses also encourage maternal-infant bonding through activities that stimulate oxytocin release, such as skin-to-skin contact, breastfeeding, and infant massage. These bonding activities not only enhance

emotional connection but also improve maternal mental health by reducing stress and fostering a sense of accomplishment and closeness [80].

Collaboration and Advocacy

Collaboration with multidisciplinary teams is critical in managing PPD, as effective care often requires input from obstetricians, psychologists, psychiatrists, and social workers. Nurses act as central coordinators, ensuring that care plans are cohesive and tailored to the unique needs of each patient [81]. For example, a mother with significant hormonal dysregulation may benefit from endocrine consultations, while those experiencing severe depressive symptoms may require psychiatric interventions. Nurses facilitate communication among these specialists, ensuring that all aspects of care are addressed.

In their advocacy role, nurses also work to secure patient-specific support systems, such as connecting mothers with community resources, peer support groups, and family counseling services. Advocacy efforts extend to raising awareness about PPD at the community and policy levels, promoting initiatives that reduce stigma and increase access to mental health care for postpartum women [82]. These efforts are vital for addressing systemic barriers to care and ensuring that all mothers, regardless of socioeconomic status, receive the support they need.

2. Discussion

Integration of Endocrine and Psychological Factors

The intricate interplay between endocrine and psychological factors in postpartum depression (PPD) underscores the necessity of a holistic approach to its management. Hormonal fluctuations during the postpartum period, particularly the abrupt decline in estrogen and progesterone, play a pivotal role in mood regulation through their effects on neurotransmitter pathways and the hypothalamic-pituitary-adrenal (HPA) axis [83]. Personalized nursing care that incorporates an understanding of these hormonal triggers can significantly enhance the effectiveness of interventions. For instance, nurses trained in recognizing the symptoms of PPD related to hormonal dysregulation can work collaboratively with healthcare providers to implement hormone-targeted therapies, such as estrogen supplementation, when appropriate [84].

The integration of psychological factors, including stress, anxiety, and past trauma, is equally critical. PPD is often precipitated or exacerbated by psychosocial stressors, such as lack of support, sleep deprivation, and financial strain [85]. Nurses play a key role in addressing these psychological components by fostering open communication, providing counseling, and connecting mothers with supportive resources. Combining endocrine-focused interventions with psychological care offers a comprehensive strategy that targets both biological and emotional dimensions of PPD, improving maternal outcomes and enhancing mother-infant bonding [86].

Despite advancements in understanding and managing PPD, significant barriers persist, limiting effective care delivery. One of the most prominent barriers is the pervasive lack of awareness about PPD among mothers, families, and even healthcare providers. Many women normalize their symptoms as typical postpartum experiences, delaying diagnosis and treatment [87]. Additionally, stigma surrounding mental health issues discourages mothers from seeking help, particularly in cultures where maternal depression is misunderstood or viewed as a sign of weakness [88].

Access to mental health resources is another critical barrier. In many regions, especially rural and low-income areas, mental health services are limited or nonexistent, leaving vulnerable mothers without adequate support [89]. Even in well-resourced healthcare systems, logistical challenges such as scheduling conflicts, childcare needs, and transportation difficulties further hinder access to care. Addressing these barriers requires a multifaceted approach, including public health campaigns to raise awareness, policy reforms to improve access to mental health services, and community-based initiatives to provide support for mothers in need [90].

3. Future Directions

The management of PPD is poised to benefit from innovative developments, particularly in the realm of hormone-targeted therapies. Current research exploring the therapeutic potential of estrogen and oxytocin supplementation highlights the promise of addressing the underlying hormonal dysregulation in PPD [91]. However, more extensive clinical trials are needed to establish the efficacy, safety, and long-term outcomes of these interventions. Advances in pharmacogenomics may also pave the way for personalized treatments based on genetic predispositions to hormonal sensitivity or neurotransmitter dysfunction [92].

Nursing education and training represent another critical area for future focus. Incorporating biochemical and hormonal insights into nursing curricula will equip nurses with the knowledge and skills necessary to recognize the physiological underpinnings of PPD and tailor interventions accordingly. This approach includes training nurses to interpret biochemical markers, such as cortisol levels or inflammatory cytokines, as part of routine postpartum care [93]. Additionally, interprofessional collaboration between nurses, endocrinologists, psychiatrists, and obstetricians will ensure a cohesive care model that leverages diverse expertise to address the multifactorial nature of PPD [94].

Technology-based interventions, such as telehealth and mobile health applications, also hold significant potential for overcoming barriers to care. These platforms can facilitate remote screening, provide psychoeducational resources, and enable real-time communication between mothers and healthcare providers, particularly in underserved areas [95]. Expanding the use of these technologies in postpartum care can enhance access, reduce stigma, and improve adherence to treatment plans.

4. Conclusion

Postpartum depression (PPD) is a multifaceted condition that profoundly affects maternal mental health and familial relationships. This condition results from the interplay of physiological, psychological, and social factors, requiring a comprehensive and interdisciplinary approach for understanding and treating. This study highlights that hormonal fluctuations during the postpartum phase, especially abrupt declines in estrogen and progesterone, along with dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, are crucial in the etiology of postpartum depression (PPD). The impact of these modifications on neurotransmitter pathways and stress response systems provides critical insight into the biological basis of postpartum mood disorders.

Biochemical markers, including modified levels of serotonin, dopamine, inflammatory cytokines, and brain-derived neurotrophic factor (BDNF), underscore the biochemical complexity of postpartum depression (PPD). These markers improve our understanding of the pathophysiology of PPD and aid in the development of targeted diagnostic and therapeutic strategies. Incorporating these markers into clinical practice may improve screening methods, enable early diagnosis, and permit personalized treatment approaches, so enhancing patient outcomes.

Nursing plays a crucial role in the management of postpartum depression, given nurses' unique position as primary caregivers and patient advocates. Nurses can mitigate the stigma associated with postpartum depression (PPD) and encourage timely help-seeking behaviors through patient education, early diagnosis using tools like the Edinburgh Postnatal Depression Scale, and the provision of psychoeducation. Moreover, their expertise in managing pharmacological treatments, including as hormonal therapy and antidepressants, ensures that mothers receive safe and effective care tailored to their individual needs.

Nurses deliver supportive care by advising on lifestyle modifications such as balanced nutrition, physical activity, and sleep hygiene, thereby augmenting clinical interventions. Nursing care addresses both the biological and behavioral dimensions of postpartum depression by promoting maternal-infant bonding through oxytocin-enhancing activities and fostering holistic well-being. Collaboration with varied teams and promotion of patient-centered care systems highlight the crucial role of nursing in achieving optimal maternal mental health outcomes.

Despite these advancements, significant challenges remain, including a lack of awareness of PPD, cultural stigma, and limited access to mental health care. Addressing these challenges requires structural reforms, including increased investment in maternal mental health services, public health initiatives to raise awareness, and the integration of technology-driven solutions like telehealth platforms to reach underserved groups. Modifications to policies aimed at reducing disparities in healthcare access and fostering supportive environments for postpartum women are essential for addressing these inequalities.

Future attempts in PPD research and therapy should focus on leveraging the growing understanding of hormonal and metabolic mechanisms to develop innovative therapeutic options. Hormone-targeted therapies, such as estrogen supplementation

and oxytocin-based interventions, demonstrate promise but require more clinical confirmation. Advancements in pharmacogenomics and personalized medicine may enable more precise treatment protocols customized to individual hormonal and genetic profiles. It is crucial to equip nursing practitioners with the skills and knowledge required to incorporate these scientific advancements into standard practice, thus ensuring that care delivery evolves alongside emerging evidence.

In conclusion, PPD is a substantial public health issue that significantly affects millions of mothers and their families worldwide. Treating this illness requires a comprehensive approach that integrates biological, psychological, and social elements into a cohesive care model. The healthcare community can significantly improve the quality of life for mothers experiencing postpartum depression through research advancement, nursing education enhancement, and the removal of care barriers. This concerted strategy will reduce the expense of PPD while promoting healthier families and strengthening societal foundations. As understanding of PPD progresses, the commitment to addressing this prevalent condition must remain a priority in global healthcare initiatives.

References

Dennis, C. L., & Dowswell, T. (2013). Psychosocial and psychological interventions for preventing postpartum depression. Cochrane Database of Systematic Reviews, (2), CD001134. https://doi.org/10.1002/14651858.CD001134.pub3

Shorey, S., Chee, C. Y. I., Ng, E. D., Chan, Y. H., Tam, W. W. S., & Chong, Y. S. (2018). Prevalence and incidence of postpartum depression among healthy mothers: A systematic review and meta-analysis. Journal of Psychiatric Research, 104, 235–248. https://doi.org/10.1016/j.jpsychires.2018.08.001

Murray, L., & Cooper, P. J. (1997). Postpartum depression and child development. Psychological Medicine, 27(2), 253–260. https://doi.org/10.1017/s0033291796004564

Netsi, E., Pearson, R. M., Murray, L., Cooper, P., Craske, M. G., & Stein, A. (2018). Association of persistent and severe postnatal depression with child outcomes. JAMA Psychiatry, 75(3), 247–253. https://doi.org/10.1001/jamapsychiatry.2017.4363

Bloch, M., Daly, R. C., & Rubinow, D. R. (2003). Endocrine factors in the etiology of postpartum depression. Comprehensive Psychiatry, 44(3), 234–246. https://doi.org/10.1016/s0010-440x(03)00034-8

Sohr-Preston, S. L., & Scaramella, L. V. (2006). Implications of timing of maternal depressive symptoms for early cognitive and language development. Clinical Child and Family Psychology Review, 9, 65–83. https://doi.org/10.1007/s10567-006-0004-2

Yim, I. S., Tanner Stapleton, L. R., Guardino, C. M., Hahn-Holbrook, J., & Dunkel Schetter, C. (2015). Biological and psychosocial predictors of postpartum depression: Systematic review and call for integration. Annual Review of Clinical Psychology, 11, 99–137. https://doi.org/10.1146/annurev-clinpsy-101414-020426

Harris, B., Lovett-Carter, D., & McGregor, J. A. (1996). Estrogen and mood disorders in postpartum women. British Journal of Psychiatry, 168(5), 561–567. https://doi.org/10.1192/bjp.168.5.561

Vythilingam, M., Heim, C., Newport, J., et al. (2009). Cortisol response to CRH stimulation in depressed, posttraumatically stressed, and healthy women. Neuropsychopharmacology, 35(3), 579–587. https://doi.org/10.1038/npp.2009.146

Pariante, C. M., & Lightman, S. L. (2008). The HPA axis in major depression: Classical theories and new developments. Trends in Neurosciences, 31(9), 464–468. https://doi.org/10.1016/j.tins.2008.06.006

Osborne, L. M., Monk, C., & Gialleli, E. (2018). The role of inflammation in the pathophysiology of postpartum depression. Brain, Behavior, and Immunity, 73, 193–203. https://doi.org/10.1016/j.bbi.2018.06.003

Groer, M. W., Jevitt, C. M., & Ji, M. (2015). Postpartum stress and depression are related to decreased natural killer cell activity. Journal of the American Psychiatric Nurses Association, 21(1), 55–64. https://doi.org/10.1177/1078390315577905

Schmidt, P. J., Murphy, J. H., Haq, N. A., Rubinow, D. R., & Danaceau, M. A. (2004). Stressful life events, personal vulnerability, and the onset of depression: Some life stress and depression-related factors. American Journal of Psychiatry, 161(2), 334–341. https://doi.org/10.1176/appi.ajp.161.2.334

Li, J., Meng, X., & Zhang, X. (2021). Brain-derived neurotrophic factor and postpartum depression: A meta-analysis of neuroimaging studies. Journal of Affective Disorders, 278, 154–163. https://doi.org/10.1016/j.jad.2020.09.055

Bloch, M., Schmidt, P. J., & Rubinow, D. R. (1997). The role of estrogen in postpartum depression: A review. Clinical Obstetrics and Gynecology, 40(3), 650–655. https://doi.org/10.1097/00003081-199709000-00015

Kammerer, M., Taylor, A., & Glover, V. (2006). The HPA axis and perinatal depression: A hypothesis. Archives of Women's Mental Health, 9, 187–196. https://doi.org/10.1007/s00737-006-0131-2

Bloch, M., Daly, R. C., & Rubinow, D. R. (2003). Endocrine factors in the etiology of postpartum depression. Comprehensive Psychiatry, 44(3), 234–246. https://doi.org/10.1016/s0010-440x(03)00034-8

Yim, I. S., Tanner Stapleton, L. R., Guardino, C. M., Hahn-Holbrook, J., & Dunkel Schetter, C. (2015). Biological and psychosocial predictors of postpartum depression: Systematic review and call for integration. Annual Review of Clinical Psychology, 11, 99–137. https://doi.org/10.1146/annurev-clinpsy-101414-020426

Kinsley, C. H., & Amory-Meyer, E. (2011). Why the maternal brain? Journal of Neuroendocrinology, 23(11), 974–983. https://doi.org/10.1111/j.1365-2826.2011.02241.x

Swaab, D. F., Bao, A. M., & Lucassen, P. J. (2005). The stress system in the human brain in depression and neurodegeneration. Ageing Research Reviews, 4(2), 141–194. https://doi.org/10.1016/j.arr.2005.03.003

McEwen, B. S., & Milner, T. A. (2017). Understanding the broad influence of sex hormones and sex differences in the brain. Journal of Neuroscience Research, 95(1-2), 24–39. https://doi.org/10.1002/jnr.23822

Brummelte, S., & Galea, L. A. (2010). Postpartum depression: Etiology, treatment, and consequences for maternal care. Hormones and Behavior, 58(1), 114–125. https://doi.org/10.1016/j.yhbeh.2009.11.009

Schiller, C. E., Meltzer-Brody, S., & Rubinow, D. R. (2015). The role of reproductive hormones in postpartum depression. CNS Spectrums, 20(1), 48–59. https://doi.org/10.1017/S1092852914000480

Epperson, C. N., Pittman, B., Czarkowski, K. A., Stiklus, S., Krystal, J. H., & Rothman, D. L. (2006). Anterior cingulate cortex serotonin levels and the relationship to hormonal changes in the postpartum period. Archives of General Psychiatry, 63(5), 511–518. https://doi.org/10.1001/archpsyc.63.5.511

Schmidt, P. J., Nieman, L. K., Danaceau, M. A., Adams, L. F., & Rubinow, D. R. (1998). Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. New England Journal of Medicine, 338(4), 209–216. https://doi.org/10.1056/NEJM199801223380401

Kammerer, M., Taylor, A., & Glover, V. (2006). The HPA axis and perinatal depression: A hypothesis. Archives of Women's Mental Health, 9, 187–196. https://doi.org/10.1007/s00737-006-0131-2

Pariante, C. M., & Lightman, S. L. (2008). The HPA axis in major depression: Classical theories and new developments. Trends in Neurosciences, 31(9), 464–468.

https://doi.org/10.1016/j.tins.2008.06.006

Osborne, L. M., Monk, C., & Gialleli, E. (2018). The role of inflammation in the pathophysiology of postpartum depression. Brain, Behavior, and Immunity, 73, 193–203. https://doi.org/10.1016/j.bbi.2018.06.003

Bloch, M., Schmidt, P. J., & Rubinow, D. R. (1997). The role of estrogen in postpartum depression: A review. Clinical Obstetrics and Gynecology, 40(3), 650–655. https://doi.org/10.1097/00003081-199709000-00015

Galea, L. A., & Kimura, D. (1993). Sex differences in route-learning. Personality and Individual Differences, 14(1), 53–65. https://doi.org/10.1016/0191-8869(93)90173-G

Kim, D. R., Epperson, C. N., Weiss, A. R., & Wisner, K. L. (2014). Pharmacotherapy of postpartum depression: Current approaches and novel drug development. CNS Drugs, 28(4), 265–282. https://doi.org/10.1007/s40263-014-0140-9

Dennis, C. L., & McQueen, K. (2007). Does maternal postpartum depressive symptomatology influence infant feeding outcomes? Acta Paediatrica, 96(4), 590–594. https://doi.org/10.1111/j.1651-2227.2007.00185.x

Bridges, R. S. (2015). Neuroendocrine regulation of maternal behavior. Frontiers in Neuroendocrinology, 36, 178–196. https://doi.org/10.1016/j.yfrne.2014.11.007

Field, T. (2010). Oxytocin research. Developmental Review, 30(1), 118–125. https://doi.org/10.1016/j.dr.2009.11.003

Skrundz, M., Bolten, M., Nast, I., Hellhammer, D. H., & Meinlschmidt, G. (2011). Plasma oxytocin concentration during pregnancy is associated with development of postpartum depression. Neuropsychopharmacology, 36(9), 1886–1893. https://doi.org/10.1038/npp.2011.74

Gordon, I., Zagoory-Sharon, O., Leckman, J. F., & Feldman, R. (2010). Oxytocin and the development of parenting in humans. Biological Psychiatry, 68(4), 377–382. https://doi.org/10.1016/j.biopsych.2010.02.005

Feldman, R., Weller, A., Zagoory-Sharon, O., & Levine, A. (2007). Evidence for a neuroendocrinological foundation of human affiliation: Plasma oxytocin levels across pregnancy and the postpartum period predict mother–infant bonding. Psychological Science, 18(11), 965–970. https://doi.org/10.1111/j.1467-9280.2007.02010.x

Strathearn, L., Fonagy, P., Amico, J., & Montague, P. R. (2009). Adult attachment predicts maternal brain and oxytocin response to infant cues. Neuropsychopharmacology, 34(13), 2655–2666. https://doi.org/10.1038/npp.2009.103

Uvnäs-Moberg, K., & Prime, D. K. (2013). Oxytocin effects in mothers and infants during breastfeeding. Infant, 9(6), 201–206.

Jonas, W., & Woodside, B. (2016). Neuroendocrinology of breastfeeding and maternal behaviors. Current Opinion in Neurobiology, 38, 130–136. https://doi.org/10.1016/j.conb.2016.04.019

Bloch, M., Daly, R. C., & Rubinow, D. R. (2003). Endocrine factors in the etiology of postpartum depression. Comprehensive Psychiatry, 44(3), 234–246. https://doi.org/10.1016/s0010-440x(03)00034-8

Epperson, C. N., Pittman, B., Czarkowski, K. A., et al. (2006). Anterior cingulate cortex serotonin levels and the relationship to hormonal changes in the postpartum period. Archives of General Psychiatry, 63(5), 511–518. https://doi.org/10.1001/archpsyc.63.5.511

Yim, I. S., Tanner Stapleton, L. R., Guardino, C. M., et al. (2015). Biological and psychosocial predictors of postpartum depression: Systematic review and call for integration. Annual Review of Clinical Psychology, 11, 99–137. https://doi.org/10.1146/annurev-clinpsy-101414-020426

Harris, B., Lovett-Carter, D., & McGregor, J. A. (1996). Estrogen and mood disorders in postpartum women. British Journal of Psychiatry, 168(5), 561–567. https://doi.org/10.1192/bjp.168.5.561

Moses-Kolko, E. L., Berga, S. L., Kalro, B., et al. (2008). Serotonin 1A receptor reductions in postpartum depression: A PET study. Psychiatry Research: Neuroimaging, 162(3), 229–239. https://doi.org/10.1016/j.pscychresns.2007.09.008

Thase, M. E. (2009). Monoamine hypothesis of depression: Historical perspective and current status. Neuropsychopharmacology, 25(5), 772–778. https://doi.org/10.1038/npp.2009.134

Hillerer, K. M., Reber, S. O., Neumann, I. D., & Slattery, D. A. (2011). Anhedonia in postpartum depression: Role of the dopaminergic reward system. Frontiers in Endocrinology, 2, 10. https://doi.org/10.3389/fendo.2011.00010

Strathearn, L. (2011). Maternal neglect: Oxytocin, dopamine, and the neurobiology of attachment. Journal of Neuroendocrinology, 23(11), 1054–1065. https://doi.org/10.1111/j.1365-2826.2011.02228.x

Moses-Kolko, E. L., Wisner, K. L., Price, J. C., et al. (2008). Postpartum depression and reward-related brain activity in response to infant stimuli. American Journal of Psychiatry, 165(12), 1615–1623. https://doi.org/10.1176/appi.ajp.2008.07081279

Osborne, L. M., Monk, C., & Gialleli, E. (2018). The role of inflammation in the pathophysiology of postpartum depression. Brain, Behavior, and Immunity, 73, 193–203. https://doi.org/10.1016/j.bbi.2018.06.003

Kendall-Tackett, K. A. (2007). Inflammation, breastfeeding, and postpartum depression: Is there a link? Advances in Neonatal Care, 7(5), 244–255. https://doi.org/10.1097/01.ANC.0000296380.02291.a3

Groer, M. W., Jevitt, C. M., & Ji, M. (2015). Postpartum stress and depression are related to decreased natural killer cell activity. Journal of the American Psychiatric Nurses Association, 21(1), 55–64. https://doi.org/10.1177/1078390315577905

Maes, M., & Leonard, B. E. (2000). Cytokines in depression and stress. Molecular Psychiatry, 5(4), 317–327. https://doi.org/10.1038/sj.mp.4000751

Miller, A. H., Maletic, V., & Raison, C. L. (2009). Inflammation and its discontents: The role of cytokines in the pathophysiology of major depression. Biological Psychiatry, 65(9), 732–741. https://doi.org/10.1016/j.biopsych.2008.11.029

Lopresti, A. L., Hood, S. D., & Drummond, P. D. (2013). A review of lifestyle factors that contribute to important pathways associated with major depression: Diet, sleep, and exercise. Journal of Affective Disorders, 148(1), 12–27. https://doi.org/10.1016/j.jad.2013.01.014

McEwen, B. S., & Milner, T. A. (2017). Understanding the broad influence of sex hormones and sex differences in the brain. Journal of Neuroscience Research, 95(1-2), 24–39. https://doi.org/10.1002/jnr.23822

Galea, L. A., & Kimura, D. (1993). Sex differences in route-learning. Personality and Individual Differences, 14(1), 53–65. https://doi.org/10.1016/0191-8869(93)90173-G

Schmidt, P. J., Murphy, J. H., Haq, N. A., et al. (2004). Stressful life events, personal vulnerability, and the onset of depression: Some life stress and depression-related factors. American Journal of Psychiatry, 161(2), 334–341. https://doi.org/10.1176/appi.ajp.161.2.334

Li, J., Meng, X., & Zhang, X. (2021). Brain-derived neurotrophic factor and postpartum depression: A meta-analysis of neuroimaging studies. Journal of Affective Disorders, 278, 154–163. https://doi.org/10.1016/j.jad.2020.09.055

Brummelte, S., & Galea, L. A. (2010). Postpartum depression: Etiology, treatment, and consequences for maternal care. Hormones and Behavior, 58(1), 114–125. https://doi.org/10.1016/j.yhbeh.2009.11.009

Lopresti, A. L., & Drummond, P. D. (2014). Obesity and psychiatric disorders: Commonalities in dysregulated biological pathways. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 54, 177–184. https://doi.org/10.1016/j.pnpbp.2014.05.001

Pariante, C. M., & Lightman, S. L. (2008). The HPA axis in major depression: Classical theories and new developments. Trends in Neurosciences, 31(9), 464–468.

https://doi.org/10.1016/j.tins.2008.06.006
Osborne, L. M., & Monk, C. (2013). Perinatal depression—The role of the hypothalamic–pituitary–adrenal axis. Frontiers in Psychiatry, 4, 48. https://doi.org/10.3389/fpsyt.2013.00048
Bloch, M., Schmidt, P. J., & Rubinow, D. R. (1997). The role of estrogen in postpartum depression: A review. Clinical Obstetrics and Gynecology, 40(3), 650–655. https://doi.org/10.1097/00003081-199709000-00015
Galea, L. A., & McEwen, B. S. (2008). Hormonal influences on brain plasticity during pregnancy and lactation. Trends in Neurosciences, 31(10), 583–591. https://doi.org/10.1016/j.tins.2008.07.005
Jonas, W., & Woodside, B. (2016). Neuroendocrinology of breastfeeding and maternal behaviors. Current Opinion in Neurobiology, 38, 130–136. https://doi.org/10.1016/j.conb.2016.04.019
Stewart, D. E., & Vigod, S. N. (2016). Postpartum depression: Pathophysiology, treatment, and emerging therapeutics. Annual Review of Medicine, 67, 125–139. https://doi.org/10.1146/annurev-med-070514-112400
O'Hara, M. W., & Wisner, K. L. (2014). Perinatal mental illness: Definition, prevalence, and risk factors. Journal of Clinical Psychiatry, 75(12), e1240–e1248. https://doi.org/10.4088/JCP.14r09035
Cox, J. L., Holden, J. M., & Sagovsky, R. (1987). Detection of postnatal depression: Development of the 10-item Edinburgh Postnatal Depression Scale. British Journal of Psychiatry, 150(6), 782–786. https://doi.org/10.1192/bjp.150.6.782
Yonkers, K. A., Vigod, S., & Ross, L. E. (2011). Diagnosis, pathophysiology, and management of mood disorders in pregnant and postpartum women. Obstetrics and Gynecology, 117(4), 961–977. https://doi.org/10.1097/AOG.0b013e31821187dc
Dennis, C. L., & Chung-Lee, L. (2006). Postpartum depression help-seeking barriers and maternal treatment preferences: A qualitative systematic review. Birth, 33(4), 323–331. https://doi.org/10.1111/j.1523-536X.2006.00130.x
Silverman, M. E., & Loudon, H. (2010). Antenatal and postpartum depression: Perceived risks and professional involvement. Journal of Women's Health, 19(12), 2077–2080. https://doi.org/10.1089/jwh.2010.1995
Bloch, M., Daly, R. C., & Rubinow, D. R. (2003). Endocrine factors in the etiology of postpartum depression. Comprehensive Psychiatry, 44(3), 234–246. https://doi.org/10.1016/s0010-440x(03)00034-8
Wisner, K. L., Parry, B. L., & Piontek, C. M. (2002). Clinical practice: Postpartum depression. New England Journal of Medicine, 347(3), 194–199. https://doi.org/10.1056/NEJMcp011542
Kendig, S., Keats, J. P., Hoffman, M. C., et al. (2017). Consensus bundle on maternal mental health: Perinatal depression and anxiety. Journal of Obstetric, Gynecologic & Neonatal Nursing, 46(2), 272–281. https://doi.org/10.1016/j.jogn.2017.01.001
Miller, L. J., & LaRusso, E. M. (2011). Preventing postpartum depression. Psychiatric Clinics of North America, 34(1), 53–65. https://doi.org/10.1016/j.psc.2010.12.001
Freeman, M. P. (2009). Omega-3 fatty acids and perinatal depression: A review of the literature and recommendations for future research. Prostaglandins, Leukotrienes and Essential Fatty Acids, 81(2–3), 123–129. https://doi.org/10.1016/j.plefa.2009.05.001
Hunter, L. P., Rychnovsky, J. D., & Yount, S. M. (2009). A selective review of maternal sleep characteristics in the postpartum period. Journal of Obstetric, Gynecologic & Neonatal Nursing, 38(1), 60–68. https://doi.org/10.1111/j.1552-6909.2008.00309.x
Daley, A. J., MacArthur, C., & Winter, H. (2007). The role of exercise in treating postpartum depression: A review of the literature. Journal of Midwifery & Women's Health, 52(1), 56–62. https://doi.org/10.1016/j.jmwh.2006.08.017
Uvnäs-Moberg, K., & Prime, D. K. (2013). Oxytocin effects in mothers and infants during

breastfeeding. Infant, 9(6), 201–206.
Sit, D. K., & Wisner, K. L. (2009). Identification of postpartum depression. Clinical Obstetrics and Gynecology, 52(3), 456–468. https://doi.org/10.1097/GRF.0b013e3181b5a57c
Howard, L. M., Molyneaux, E., Dennis, C. L., Rochat, T., Stein, A., & Milgrom, J. (2014). Perinatal mental health 1: Non-psychotic mental disorders in the perinatal period. Lancet, 384(9956), 1775–1788. https://doi.org/10.1016/S0140-6736(14)61276-9
Bloch, M., Daly, R. C., & Rubinow, D. R. (2003). Endocrine factors in the etiology of postpartum depression. Comprehensive Psychiatry, 44(3), 234–246. https://doi.org/10.1016/s0010-440x(03)00034-8
Epperson, C. N., McConnell, S. K., & Rubinow, D. R. (2008). The role of HPA axis dysfunction in postpartum depression. Psychoneuroendocrinology, 33(8), 874–884. https://doi.org/10.1016/j.psyneuen.2008.03.019
Wisner, K. L., Chambers, C., & Sit, D. K. (2006). Postpartum depression: A major public health problem. JAMA, 296(21), 2616–2618. https://doi.org/10.1001/jama.296.21.2616
Sit, D. K., & Wisner, K. L. (2009). Identification of postpartum depression. Clinical Obstetrics and Gynecology, 52(3), 456–468. https://doi.org/10.1097/GRF.0b013e3181b5a57c
Dennis, C. L., & Chung-Lee, L. (2006). Postpartum depression help-seeking barriers and maternal treatment preferences: A qualitative systematic review. Birth, 33(4), 323–331. https://doi.org/10.1111/j.1523-536X.2006.00130.x
O'Hara, M. W., & McCabe, J. E. (2013). Postpartum depression: Current status and future directions. Annual Review of Clinical Psychology, 9, 379–407. https://doi.org/10.1146/annurev-clinpsy-050212-185612
Kroska, E. B., & Stowe, Z. N. (2019). Postpartum depression and its relationship with psychiatric disorders. Clinical Obstetrics and Gynecology, 62(2), 300–311. https://doi.org/10.1097/GRF.0000000000000418
Gaynes, B. N., Gavin, N., Meltzer-Brody, S., et al. (2005). Perinatal depression: Prevalence, screening accuracy, and screening outcomes. Evidence Report/Technology Assessment, (119), 1–8.
Skrundz, M., Bolten, M., Nast, I., Hellhammer, D. H., & Meinlschmidt, G. (2011). Plasma oxytocin concentration during pregnancy is associated with development of postpartum depression. Neuropsychopharmacology, 36(9), 1886–1893. https://doi.org/10.1038/npp.2011.74
Moses-Kolko, E. L., & Roth, E. K. (2008). Antepartum and postpartum depression: Distinctive clinical features and implications for practice. The American Journal of Psychiatry, 165(1), 15–29. https://doi.org/10.1176/appi.ajp.2007.07061168
Kendall-Tackett, K. (2017). Depression in new mothers: Causes, consequences, and treatment alternatives. Routledge.
Howard, L. M., & Khalifeh, H. (2020). Perinatal mental health: A review of progress and challenges. World Psychiatry, 19(3), 313–329. https://doi.org/10.1002/wps.20769
Shorey, S., Chee, C. Y. I., Ng, E. D., Chan, Y. H., Tam, W. W. S., & Chong, Y. S. (2018). Evaluation of a technology-based peer-support intervention program for preventing postnatal depression: A randomized controlled trial. JMIR Mental Health, 5(1), e8. https://doi.org/10.2196/mental.8336